GlassScriptPhysician profile
Noam Z Drazin
NPI 1952313520
$1,423,667.47
in general payments reported to CMS, 2019-2025
54 companies · $149K in 2025
The $149K reported for 2025 was more than what 99% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260K · 2020: $151K · 2021: $262K · 2022: $210K · 2023: $201K · 2024: $191K · 2025: $149K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $452K · Travel and Lodging: $75K · Food and Beverage: $11K · Consulting Fee: $3,270 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $451,970.00 |
| Travel and Lodging | $74,671.88 |
| Food and Beverage | $10,633.49 |
| Consulting Fee | $3,270.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $845,378.26 | 2019-2025 | Tagrisso, Imfinzi, Calquence |
| Lilly USA, LLC | $268,668.57 | 2019-2025 | Verzenio, Retevmo, Jaypirca |
| Daiichi Sankyo INC. | $146,008.10 | 2019-2025 | Enhertu, Datroway |
| Amgen INC. | $76,387.10 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Seagen INC. | $40,251.97 | 2019-2023 | Tukysa |
| Eli Lilly and Company | $14,089.87 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $13,781.83 | 2019-2023 | Opdivo |
| Beigene USA, INC. | $4,069.23 | 2020-2023 | Brukinsa |
| Abbvie INC. | $2,889.67 | 2019-2023 | Venclexta |
| Janssen Biotech, INC. | $2,305.55 | 2019-2023 | |
| Dova Pharmaceuticals | $1,526.55 | 2019-2021 | |
| Pfizer INC. | $1,424.66 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $638.00 | 2019-2023 | Keytruda |
| Novartis Pharmaceuticals Corporation | $544.39 | 2019-2022 | |
| Incyte Corporation | $520.77 | 2020-2024 | Jakafi, Monjuvi, Pemazyre |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noam Drazin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.